Spike Protein Deletions Linked to COVID-19 Surges: Preprint

Researchers find that surges in COVID-19 case numbers are associated with deletions in the SARS-CoV-2 genome in an antigenic site of the spike protein. Some of these mutations are present in vaccine breakthrough infections or reinfections.

Written byAlejandra Manjarrez, PhD
| 4 min read
an illustration of the sars-cov-2 spike protein in purple tethered to the viral membrane in dark gray

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ABOVE: © ISTOCK.COM, DESIGN CELLS

The genomic stability of SARS-CoV-2 that scientists had first expected has been disrupted by the emergence of different variants over the course of the COVID-19 pandemic. The N-terminal domain (NTD) of the virus’s spike protein has appeared as a potentially mutable structure—scientists have reported it has deletion-prone regions that may allow the virus to escape antibody neutralization. According to a preprint posted to medRxiv June 12, the prevalence of these deletions increased during surges of COVID-19 cases worldwide. The study’s authors also report the presence of NTD deletions in SARS-CoV-2 samples from COVID-19 patients who had either been infected before or who were already fully vaccinated.

The team hypothesizes these deletions could assist the virus in evading immunity, potentially playing a role in surges and vaccine breakthrough infections. The ideas in this manuscript are thought-provoking, says virologist Kevin McCarthy of the University of Pittsburgh who ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • alejandra manjarrez

    Alejandra Manjarrez is a freelance science journalist who contributes to The Scientist. She has a PhD in systems biology from ETH Zurich and a master’s in molecular biology from Utrecht University. After years studying bacteria in a lab, she now spends most of her days reading, writing, and hunting science stories, either while traveling or visiting random libraries around the world. Her work has also appeared in Hakai, The Atlantic, and Lab Times.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies